CDIO Overview

Cardio Diagnostics Holdings, Inc. is an artificial intelligence-powered precision cardiovascular medicine company. The Company develops and commercializes a series of products for various types of cardiovascular disease and associated co-morbidities, including coronary heart disease (CHD), stroke, heart failure and diabetes, by leveraging its artificial intelligence (AI)-driven Integrated Genetic-Epigenetic Engine. Its first product, Epi+Gen CHD, is an epigenetics-based clinical blood test capable of assessing near-term (three-year) risk for CHD, and its second product, PrecisionCHD, is an epigenetics-based clinical blood test for the detection of CHD. CardioInnovate360 is a research use only (RUO) solution to support the discovery, development, and validation of biopharmaceuticals for the assessment and management of cardiovascular diseases. HeartRisk is a cardiovascular risk intelligence platform that combines insights from anonymized and aggregated clinical cardiovascular data.

Wall Street analysts forecast CDIO stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CDIO is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Cardio Diagnostics Holdings Inc revenue for the last quarter amounts to 2.85K USD, decreased -56.61

Cardio Diagnostics Holdings Inc. EPS for the last quarter amounts to -0.98 USD, decreased -43.35

Cardio Diagnostics Holdings Inc (CDIO) has 13 emplpoyees as of March 02 2026.

Today CDIO has the market capitalization of 11.96M USD.